BDX

Becton Dickinson is a high-quality, defensive medical-instruments franchise: FY2025 revenue grew 8.2% to $21.8B, operating income rose 7.6% to $2.58B, R&D was up 6.3% to $1.26B, and the auditor (Ernst & Young) issued an unqualified opinion with internal controls deemed effective as of 9/30/2025. The top line is the healthiest it has been in five years. The problem is that growth is not reaching the bottom line: net income of $1.68B was down 1.6% and is actually *below* FY2021's $2.09B despite ~14% more revenue, diluted EPS slipped 0.7% to $5.82, net margin is a thin 7.7%, and ROE is just 6.6% — modest for a franchise of this caliber. Margins are being compressed, exactly consistent with the MD&A/Risk Factor narrative around heightened inflation, tariffs and 'fluctuations in the cost and availability of oil-based resins,' sterilization-service and sole-source supplier dependence, and cost-containment pressure including 'expansion of the volume-based procurement process in China.'

The balance sheet adds caution rather than comfort. Cash fell 62.7% to just $641M against ~$19.2B of total debt ($17.6B long-term + $1.56B current), and operating cash flow declined 10.8% to $3.43B even as the company paid $1.20B in dividends and bought back $1.00B of stock. The current ratio is a slim ~1.1x. None of this signals distress — D&A of $2.46B and steady OCF comfortably service the obligations — but the depleted cash cushion and leverage leave little margin for error if tariff/resin cost pressure persists.